Two of the biggest challenges in treating advanced prostate cancer are varying responses and acquired resistance to AR targeted therapy. We seek to understand the mechanisms of AR targeted therapy, to identify novel biomarkers, and to develop therapeutic approaches to prevent or overcome resistance. There are two major directions in my lab:

1. Reveal the mechanism conferring lineage plasticity-driven resistance and develop novel combination therapy to overcome resistance
2. Identify novel tumor suppressors and oncogenes mediating therapy resistance and explore new druggable target to overcome resistance